Global Development Lead (GDL) , Clinical Development – Lung Cancer

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines’ most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning. The GDL functions as the s...